Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2015-05-06 |
Kymab (UK) |
US $90 million (€80.45 million) |
series B financing round |
The Wellcome Trust (UK) the Bill & Melinda Gates Foundation (USA) Woodford Patient Capital Trust (UK) Malin Corporation (UK) |
Infectious diseases |
Series B financing round |
2015-05-05 |
GW Pharmaceutical (UK) |
$179.2 million |
private placement |
|
CNS diseases - Neurological diseases |
Private placement |
2015-05-05 |
Blueprint Medicines (USA - MA) |
$168.6 million |
IPO |
|
Cancer - Oncology - Genetic diseases |
IPO |
2015-05-05 |
Themis Bioscience (Austria) |
€ 7 million |
series B financing round |
Wellington Partners (Germany - UK) Omnes Capital (formerly Crédit Agricole Private Equity) (France) - Ventech (France) |
Infectious diseases |
Series B financing round |
2015-05-05 |
Inovio Pharmaceuticals (USA - PA) |
$82.1 million |
private placement |
|
Cancer - Oncology - Infectious diseases |
Private placement |
2015-05-01 |
Oxford Biomedica (UK) |
$50 million |
loan |
Oberland Capital Healthcare (USA - NY) |
Cancer - Oncology - Rare diseases - Ophtalmological diseases |
Loan |
2015-05-01 |
Horizon Discovery (UK) |
£25 million |
private placement |
|
Technology - Services |
Private placement |
2015-04-30 |
Newron Pharmaceuticals (Italy) |
CHF 24.3 million (€ 23.2 - $ 25.5 million) |
capital increase |
current institutional shareholders and institutional investors from Europe and the U.S., including J.P. Morgan Asset Management (USA), Aviva (UK), Investor AB (Sweden) Sphera Global HealthCare Fund (Israel) Nyenburgh (The Netherlands) |
CNS diseases - Neurological diseases - Neurodegenerative diseases |
Capital increase |
2015-04-30 |
Pfenex (USA - CA) |
$38 million |
private placement |
|
|
Private placement |
2015-04-29 |
CRISPR Therapeutics (Switzerland) |
$ 89 million |
series B financing round |
SR One (UK) Celgene (USA - NJ) New Enterprise Associates (NEA) (USA - MD) Abingworth (UK) Versant Ventures (USA - CA) |
Genetic diseases - Rare diseases |
Series B financing round |
2015-04-29 |
Stemcells (USA - CA) |
$25 million |
private placement |
|
Rare diseases - Regenerative medicine |
Private placement |
2015-04-29 |
cytena (Germany) |
€ 1.1 million |
financing round |
High-Tech Gründerfonds (HTGF) (Germany) private investor |
Technology - Services |
Financing round |
2015-04-29 |
Epigenomics (Germany - USA) |
€ 2.77 million |
grant |
European Commission’s Horizon 2020 programme |
Cancer - Oncology - Diagnostic |
Grant |
2015-04-27 |
Pep Therapy (France) |
€1.3 million |
financing round |
Seventure Partners (France) Bernard Majoie (France) |
Cancer - Oncology |
Financing round |
2015-04-25 |
Ose Pharma (France) |
€ 21.1 million |
IPO |
|
Cancer - Oncology |
IPO |
2015-04-23 |
Nordic Nanovector (Norway) |
NOK 575 million (€ 66.6 million) |
IPO |
|
Cancer - Oncology - Rare diseases |
IPO |
2015-04-23 |
Biotie Therapies (Finland) |
€ 95 million |
capital increase, IPO |
Vivo Capital (USA - CA) OrbiMed (USA - NY) Versant Ventures (USA - CA) Baupost Group (USA - MA) |
Neurodegenerative diseases - CNS diseases |
IPO |
2015-04-21 |
Sage Therapeutics (USA - MA) |
$138 million (€128.4 million) |
private placement |
|
CNS diseases - Neurological diseases |
Private placement |
2015-04-21 |
Dimension Therapeutics (USA - MA) |
$65 Million |
series B financing round |
New Leaf Venture Partners (USA - NY - CA) Jennison Associates Partner Fund Management (USA) RA Capital Management (USA - MA) Rock Springs Capital (USA - MD) Tourbillon Global Ventures (USA) Fidelity Biosciences (USA - MA) OrbiMed (USA - NY) |
Rare diseases - Genetic diseases |
Series B financing round |
2015-04-21 |
Sensorion (France) |
€ 8.2 million |
IPO |
|
Otorhinolaryngology |
IPO |